ArticleScientific reports2020
Low expression of Talin1 is associated with advanced pathological features in colorectal cancer patients.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Oncogenic role of talin-1 in glioma: Association with poor prognosis and regulation of the TGF-beta signaling pathway.Translational oncology · 2026Article
- Talin1 is downregulated in testicular germ cell tumors according to combined bioinformatics and experimental approaches.Scientific reports · 2026Article
- TLN1 interacts with NGFR and suppresses the development of castration-resistant prostate cancer by upregulating NGFR.Frontiers in immunology · 2026Article
- Genome-wide screening and validation of exosome-derived TLN1 as a regulator of epithelial-mesenchymal transition in lung cancer.Scientific reports · 2025Article
- Talin1 Ser425 phosphorylation promotes colorectal cancer progression and metastasis.Translational cancer research · 2025Article
- Nuclear Expression of Dynamin 2 Is Associated With Tumor Aggressiveness in Bladder Cancer Patients: A Bioinformatics and Experimental Approach.Cancer reports (Hoboken, N.J.) · 2024Article
- TLN1: an oncogene associated with tumorigenesis and progression.Discover oncology · 2024Review
- Proteomic Signature of Extracellular Vesicles Associated with Colorectal Cancer.Molecules (Basel, Switzerland) · 2023Article
- High expression of Talin-1 is associated with tumor progression and recurrence in melanoma skin cancer patients.BMC cancer · 2023Article
- The Association Between Higher Expression of Talin-1 and the Reduced Survival Rate in Ovarian Serous Carcinoma Patients.Iranian journal of pathology · 2023Article
- Overexpression of melanoma-associated antigen A2 has a clinical significance in embryonal carcinoma and is associated with tumor progression.Journal of cancer research and clinical oncology · 2022Article
- Co-expression of cancer-testis antigens of MAGE-A6 and MAGE-A11 is associated with tumor aggressiveness in patients with bladder cancer.Scientific reports · 2022Article
- Prognostic value of Talin-1 in renal cell carcinoma and its association with B7-H3.Cancer biomarkers : section A of Disease markers · 2022Article
- Upregulated Talin1 synergistically boosts β-estradiol-induced proliferation and pro-angiogenesis of eutopic and ectopic endometrial stromal cells in adenomyosis.Reproductive biology and endocrinology : RB&E · 2021Article
- Expression of Talin-1 in endometriosis and its possible role in pathogenesis.Reproductive biology and endocrinology : RB&E · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To explore the proper prognostic markers for the likelihood of metastasis in CRC patients. Seventy-seven fresh CRC samples were collected to evaluate the mRNA level of the selected marker using Real-time PCR. Moreover, 648 formalin-fixed paraffin-embedded CRC tissues were gathered to evaluate protein expression by immunohistochemistry (IHC) on tissue microarrays. The results of Real-Time PCR showed that low expression of Talin1 was significantly associated with advanced TNM stage (p = 0.034) as well as gender (p = 0.029) in mRNA levels. Similarly, IHC results indicated that a low level of cytoplasmic expression of Talin1 was significantly associated with advanced TNM stage (p = 0.028) as well as gender (p = 0.009) in CRC patients. Moreover, decreased expression of cytoplasmic Talin1 protein was found to be a significant predictor of worse disease-specific survival (DSS) (p = 0.011) in the univariate analysis. In addition, a significant difference was achieved (p = 0.039) in 5-year survival rates of DSS: 65% for low, 72% for moderate, and 88% for high Talin1 protein expression. Observations showed that lower expression of Talin1 at both the gene and protein level may drive the disparity of CRC patients' outcomes via worse DSS and provide new insights into the development of progression indicators because of its correlation with increased tumor aggressiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.